Stockreport

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc.  (SPRB) 
PDF Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of [Read more]